Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.33 |
| ▸ | ESR1 | P03372 | 1/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19218340 | 1.00 | MEN1 (0.40) | MEN1KMT2AKDM4ELMNAMAPT | |
| SCHEMBL17854569 | 0.99 | MEN1 (0.41) | MEN1KMT2AKDM4ELMNAMAPT | |
| SCHEMBL19218329 | 0.96 | MEN1 (0.39) | MEN1KMT2AKDM4ELMNAMAPT | |
| SCHEMBL19218336 | 0.96 | MEN1 (0.42) | MEN1KMT2AKDM4ELMNAMAPT | |
| SCHEMBL20466622 | 0.95 | MEN1 (0.40) | MEN1KMT2AKDM4ELMNAMAPT | |
| SCHEMBL17854565 | 0.95 | MEN1 (0.44) | MEN1KMT2AKDM4ELMNAMAPT | |
| SCHEMBL19218369 | 0.93 | MEN1 (0.44) | MEN1KMT2AKDM4ELMNAMAPT | |
| SCHEMBL21141336 | 0.93 | MEN1 (0.37) | MEN1KMT2AKDM4ELMNAMAPT | |
| SCHEMBL19218371 | 0.93 | MEN1 (0.41) | MEN1KMT2AKDM4ELMNAMAPT | |
| SCHEMBL19218360 | 0.93 | PDK2 (0.35) | MEN1KMT2AKDM4ELMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170229649-A1 | COMPOUND, MATERIAL FOR ORGANIC ELECTROLUMINESCENT ELEMENTS, ORGANIC ELECTROLUMINESCENT ELEMENT AND ELECTRONIC DEVICE | IDEMITSU KOSAN CO., LTD. (JP) | 2017-08-10 | — | — | US | disclosed |
| US-20170229649-A1 | COMPOUND, MATERIAL FOR ORGANIC ELECTROLUMINESCENT ELEMENTS, ORGANIC ELECTROLUMINESCENT ELEMENT AND ELECTRONIC DEVICE | IDEMITSU KOSAN CO., LTD. (JP) | 2017-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170229649-A1 | COMPOUND, MATERIAL FOR ORGANIC ELECTROLUMINESCENT ELEMENTS, ORGANIC ELECTROLUMINESCENT ELEMENT AND ELECTRONIC DEVICE | L1CAM, LEF1, PIEZO1 | MEN1 573/4885KMT2A 1240/4885KDM4E 2978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.